To obtain a lipid aggregate which is specifically selectively transferred into lymph system, especially lymph node and manifests anti-HIV activity by making the lipid aggregate include a specific lipid analogue type compound into a fat-soluble microparticle carrier.
This lipid aggregate is obtained by including (A) a lipid analogue type compound represented by formula I {R1 is a long-chain fatty acid residue, etc.; R2 is H, a hydrocarbon residue, etc.; X is a group of formula II [R3 is H or azide; R4 is H or a lower alkyl; Y is a base represented by formula III, formula IV or formula V (R5 is a halogen, etc.; R6 is a lower alkyl, etc.; R7 is amino, etc.; R8 is a halogen, etc.; R9 is an amino, etc.)], and developing anti- HIV activity in the presence of at least phospholipase D or C into (B) a fat- soluble microparticle carrier (e.g. liposome or emulsion). The component A is preferably contained in an amount of usually 10-100 mol.% based on the component B in the above aggregate.
YAMAMOTO AKIRA
FUKUZUMI MASANORI
MAGAFUCHI TOSHIYUKI
